Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer

Rosario Vincenzo Iaffaioli, Anna Tortoriello, Gaetano Facchini, Michele Santangelo, Luigi Bucci, Landino Fei, Natale Di Martino, Giovanni Mantovani, Francesco Caponigro

Research output: Contribution to journalArticle

Abstract

44 patients with advanced breast cancer were treated with high-dose epirubicin (130 mg/sqm), because of its steep dose-response curve. Lonidamine and alpha interferon were administered as well with the aim of increasing epirubicin uptake and overcoming drug resistance. Granulocyte-colony stimulating factor support was provided. 14 complete responses and 22 partial responses were observed in 40 evaluable patients for a 90% overall response rate. Median duration of response was 12 months for complete responders, 7 months for partial responders. In two cases the complete response has lasted for more than two years. Myelosuppression, infection, and cardiac toxicity were the main treatment-related toxic effects. These results are encouraging enough to justify a randomized comparison of our chemotherapy program with standard regimens used in advanced breast cancer.

Original languageEnglish
Pages (from-to)243-248
Number of pages6
JournalBreast Cancer Research and Treatment
Volume35
Issue number3
DOIs
Publication statusPublished - Sep 1995

Keywords

  • advanced breast cancer
  • alpha interferon
  • epirubicin
  • high-dose chemotherapy
  • lonidamine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer'. Together they form a unique fingerprint.

  • Cite this